Bayer (BAYRY.PK -1.7%) says results of a Phase III study for its blood clot prevention drug...

|About: Bayer A.G. ADR (BAYRY)|By:, SA News Editor

Bayer (BAYRY.PK -1.7%) says results of a Phase III study for its blood clot prevention drug rivaroxaban show it is highly effective in preventing recurrent strokes. The treatment, which is also marketed by Johnson & Johnson (JNJ +1.1%), has a potential annual market of $2.8B. (PR)